TapewireFind a company

person · Reporting owner

Zinman Jon

Disclosed activity across 3 companies

Tapewire entity
25916
SEC CIK
0002001886

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
AZUL SAAZUL · Entity 4770Member of Strategy CommitteeJune 15, 2026June 17, 2026
Keenova Therapeutics plcNONE · Entity 28960DirectorJuly 15, 2026July 18, 2026
QVC Group, Inc.QVCG · Entity 1478DirectorAugust 06, 2026August 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AZUL SA

Report date June 15, 2026 · Filed June 17, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect980,860 Reported balance After 2026-06-15 transaction · row 1
1 source row

Row 1 · 2026-06-15 · Grant · Acquired 980,860 · Balance 980,860

F1: Represents a grant of 980,860 rights to acquire common shares pursuant to the terms of the Issuer's Restricted Shares Granting Plan and applicable documentation thereunder ("Restricted Shares"). The Restricted Shares vest over four years as follows: approximately 40% vested on the grant date and approximately 20% will vest on each of May 5, 2027, May 5, 2028 and May 5, 2029, contingent on the reporting person's continued service on each applicable vesting date

F2: In the event that the Issuer does not hold sufficient treasury shares for the settlement of the Restricted Shares on the applicable vesting date, the Reporting Person will be required to subscribe for the Restricted Shares for a nominal price of R$1.00 (one Brazilian real) for all Restricted Shares subject to vesting.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of 980,860 rights to acquire common shares pursuant to the terms of the Issuer's Restricted Shares Granting Plan and applicable documentation thereunder ("Restricted Shares"). The Restricted Shares vest over four years as follows: approximately 40% vested on the grant date and approximately 20% will vest on each of May 5, 2027, May 5, 2028 and May 5, 2029, contingent on the reporting person's continued service on each applicable vesting date

F2: In the event that the Issuer does not hold sufficient treasury shares for the settlement of the Restricted Shares on the applicable vesting date, the Reporting Person will be required to subscribe for the Restricted Shares for a nominal price of R$1.00 (one Brazilian real) for all Restricted Shares subject to vesting.

Keenova Therapeutics plc

Report date July 15, 2026 · Filed July 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect39,078 Reported balance After 2026-07-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-07-15 · Grant · Acquired 4,406 · Balance 39,078

F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.

F2: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.

F2: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.

QVC Group, Inc.

Report date August 06, 2026 · Filed August 06, 2026

This filing explicitly reported no securities owned.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 15, 2026 Filed Jul 18, 2026 01:56 UTC Keenova Therapeutics plc NONE · Entity 28960 GrantRestricted Stock Units · Derivative 4,406 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-084778 · tm2620763-7_4seq1.xml · derivative · entry 1

Zinman Jon · CIK 0002001886 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,078

Underlying: Ordinary Shares · 4,406 shares

Expires not disclosed

F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.

F2 · derivative.exercise_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.

F2 · derivative.expiration_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.

Read SEC document
June 15, 2026 Filed Jun 17, 2026 23:06 UTC AZUL SA AZUL · Entity 4770 GrantCommon Shares 980,860 $0.00 $0.00
Disclosure

SEC source: 0001123292-26-000903 · form4.xml · nonDerivative · entry 1

Zinman Jon · CIK 0002001886 · Member of Strategy Committee

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 980,860

F1 · shares: Represents a grant of 980,860 rights to acquire common shares pursuant to the terms of the Issuer's Restricted Shares Granting Plan and applicable documentation thereunder ("Restricted Shares"). The Restricted Shares vest over four years as follows: approximately 40% vested on the grant date and approximately 20% will vest on each of May 5, 2027, May 5, 2028 and May 5, 2029, contingent on the reporting person's continued service on each applicable vesting date

F2 · price: In the event that the Issuer does not hold sufficient treasury shares for the settlement of the Restricted Shares on the applicable vesting date, the Reporting Person will be required to subscribe for the Restricted Shares for a nominal price of R$1.00 (one Brazilian real) for all Restricted Shares subject to vesting.

Read SEC document
June 02, 2026 Filed Jun 4, 2026 20:10 UTC Keenova Therapeutics plc NONE · Entity 28960 Exercise / conversionRestricted Stock Units · Derivative 4,882 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-070519 · tm2616870-2_4seq1.xml · derivative · entry 2

Zinman Jon · CIK 0002001886 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,672

Underlying: Ordinary Shares · 4,882 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.

F3 · derivative.exercise_date: The RSUs, which were granted on August 14, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.

F3 · derivative.expiration_date: The RSUs, which were granted on August 14, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.

Read SEC document
June 02, 2026 Filed Jun 4, 2026 20:10 UTC Keenova Therapeutics plc NONE · Entity 28960 Exercise / conversionOrdinary Shares 4,882 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-26-070519 · tm2616870-2_4seq1.xml · nonDerivative · entry 1

Zinman Jon · CIK 0002001886 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By JZ Advisors LLC

Disclosed balance after: 12,913

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.

F2 · ownership.direct: Shares are held directly by JZ Advisors LLC, a limited liability company, of which the Reporting Person is a 100% owner and managing member.

Read SEC document
February 23, 2026 Filed Feb 26, 2026 01:59 UTC Keenova Therapeutics plc NONE · Entity 28960 GrantRestricted Stock Units · Derivative 3,984 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-019929 · tm267115-8_4seq1.xml · derivative · entry 1

Zinman Jon · CIK 0002001886 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,554

Underlying: Ordinary Shares · 3,984 shares

Expires not disclosed

F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.

F2 · derivative.exercise_date: Each RSU will fully vest on February 23, 2027.

F2 · derivative.expiration_date: Each RSU will fully vest on February 23, 2027.

Read SEC document
January 01, 2026 Filed Jan 5, 2026 23:05 UTC Keenova Therapeutics plc NONE · Entity 28960 Exercise / conversionRestricted Stock Units · Derivative 4,384 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-000785 · tm261751-8_4seq1.xml · derivative · entry 2

Zinman Jon · CIK 0002001886 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,570

Underlying: Ordinary Shares · 4,384 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.

F3 · derivative.exercise_date: On February 19, 2024, the Reporting Person was granted 10,942 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 4 below.

F3 · derivative.expiration_date: On February 19, 2024, the Reporting Person was granted 10,942 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 4 below.

F4 · balance_after: Reflects that the Reporting Person received 6,711 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health.

Read SEC document
January 01, 2026 Filed Jan 5, 2026 23:05 UTC Keenova Therapeutics plc NONE · Entity 28960 Exercise / conversionOrdinary Shares 4,384 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-26-000785 · tm261751-8_4seq1.xml · nonDerivative · entry 1

Zinman Jon · CIK 0002001886 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By JZ Advisors LLC

Disclosed balance after: 8,031

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.

F2 · ownership.direct: Shares are held directly by JZ Advisors LLC, a limited liability company, of which the Reporting Person is a 100% owner and managing member.

Read SEC document
August 14, 2025 Filed Aug 19, 2025 01:07 UTC Keenova Therapeutics plc NONE · Entity 28960 GrantRestricted Stock Units · Derivative 4,062 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-079950 · tm2523680-9_4seq1.xml · derivative · entry 1

Zinman Jon · CIK 0002001886 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,243

Underlying: Ordinary Shares · 4,062 shares

Expires not disclosed

F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.

F2 · derivative.exercise_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.

F2 · derivative.expiration_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.

Read SEC document
July 31, 2025 Filed Aug 5, 2025 00:53 UTC Keenova Therapeutics plc NONE · Entity 28960 GrantRestricted Stock Units · Derivative 21,886 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-073797 · tm2522414-27_4seq1.xml · derivative · entry 1

Zinman Jon · CIK 0002001886 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,181

Underlying: Ordinary Shares · 21,886 shares

Expires not disclosed

F1 · derivative.exercise_price: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer.

F2 · derivative.exercise_date: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into a restricted unit ("RSU"). Each RSU will fully vest on December 25, 2026.

F2 · derivative.expiration_date: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into a restricted unit ("RSU"). Each RSU will fully vest on December 25, 2026.

Read SEC document
January 01, 2025 Filed Jan 2, 2025 22:05 UTC Keenova Therapeutics plc NONE · Entity 28960 Exercise / conversionRestricted Stock Units · Derivative 3,647 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-000378 · tm2432211-16_4seq1.xml · derivative · entry 2

Zinman Jon · CIK 0002001886 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,295

Underlying: Ordinary Shares · 3,647 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the issuer at one share per RSU.

F3 · derivative.exercise_date: On February 19, 2024, the reporting person was granted 10,942 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024.

F3 · derivative.expiration_date: On February 19, 2024, the reporting person was granted 10,942 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024.

Read SEC document
January 01, 2025 Filed Jan 2, 2025 22:05 UTC Keenova Therapeutics plc NONE · Entity 28960 Exercise / conversionOrdinary Shares 3,647 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-25-000378 · tm2432211-16_4seq1.xml · nonDerivative · entry 1

Zinman Jon · CIK 0002001886 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By JZ Advisors LLC

Disclosed balance after: 3,647

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the issuer at one share per RSU.

F2 · ownership.direct: Shares are held directly by JZ Advisors LLC, a limited liability company, of which the reporting person is a 100% owner and managing member.

Read SEC document
February 19, 2024 Filed Feb 20, 2024 21:20 UTC Keenova Therapeutics plc NONE · Entity 28960 GrantRestricted Stock Units · Derivative 10,942 $0.00 $0.00
Disclosure

SEC source: 0001104659-24-025536 · tm245307-19_4seq1.xml · derivative · entry 1

Zinman Jon · CIK 0002001886 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,942

Underlying: Ordinary Shares · 10,942 shares

Expires not disclosed

F1 · derivative.exercise_price: Upon vesting, each restricted stock unit (the "RSU") will be settled in ordinary shares of the issuer at one share per RSU.

F2 · derivative.exercise_date: The RSUs will vest ratably on each of the first three anniversaries of January 1, 2024.

F2 · derivative.expiration_date: The RSUs will vest ratably on each of the first three anniversaries of January 1, 2024.

F3 · ownership.direct: The Reporting Person is an employee of Silver Point Capital, L.P. ("Silver Point"). Mr. Zinman has an understanding with Silver Point pursuant to which he will hold any compensation received as a director for the benefit of Silver Point and certain of its affiliates. Mr. Zinman disclaims beneficial ownership of any of the Issuer's securities held by Silver Point or its affiliates.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.